Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.44 |
| ▸ | PI4KA | P42356 | 6/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 6/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 6/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.41 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754966 | 0.83 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL23185942 | 0.82 | ADORA2A (0.47) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL24239256 | 0.81 | ADORA2A (0.43) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21943159 | 0.78 | ADORA2A (0.57) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21127683 | 0.76 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21138132 | 0.75 | MAP4K4 (0.44) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21942687 | 0.73 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21126202 | 0.73 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21138224 | 0.73 | RET (0.42) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL763189 | 0.71 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA2A 69/4885ADORA1 36/4885ADORA2B 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.